Local cytokines and clinical symptoms in children with allergic rhinitis after different treatments

correspondence: gesmar RS Segundo Department of Pediatrics, Universidade Federal de Uberlandia, Uberlandia, Brazil Tel +55 34 3236 6299 Fax +55 34 3218 2333 email gesmar2@pop.com.br Background: Therapy for allergic rhinitis aims to control symptoms and improve the quality of life. The treatment of allergic rhinitis includes allergen avoidance, environmental controls, pharmacologic treatment, and specific immunotherapy. Objectives: The aim of this study is to evaluate the clinical changes and the levels of interferon-γ (IFN-γ) and interleukin-5 (IL-5) in nasal lavage fluid from children with allergic rhinitis after different types of pharmacologic treatment (mometasone, montelukast, or desloratadine). Methods: Twenty-four children aged from six to 12 years with moderate persistent allergic rhinitis were randomized into three groups receiving monotherapy treatment over four weeks: nasal corticosteroid (mometasone), leukotriene modifier (montelukast), or antihistamine (desloratadine). The perception of symptom improvement during the medication use was evaluated at the end of the treatment. Samples of nasal lavage fluid were collected before and after treatment for measuring IFN-γ and IL-5 cytokines by ELISA. Results: All parents perceived an improvement in symptoms. Significant enhancement was seen in the mometasone group compared to those with montelukast (P = 0.01) and desloratadine (P = 0.02). No significant differences were found among the three groups in the levels of IL-5 and IFN-γ in nasal fluid at baseline or after treatment. Only the group treated with mometasone showed a slight but significant reduction in IL-5 levels after the treatment period as compared with levels before the treatment (P = 0.0469). Conclusion: The group treated with mometasone showed better improvement of clinical symptoms and a slight reduction in IL-5 levels in the nasal fluid. This may indirectly reflect the relative immunomodulatory effects of the drugs tested.

[1]  M. Rottem.  [Allergic rhinitis and its impact on asthma]. , 2010, Harefuah.

[2]  E. Meltzer,et al.  Molecular and clinical pharmacology of intranasal corticosteroids: clinical and therapeutic implications , 2008, Allergy.

[3]  J. Mullol,et al.  Development and validation of a new Spanish instrument to measure health-related quality of life in patients with allergic rhinitis: the ESPRINT questionnaire. , 2007, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

[4]  G. Passalacqua,et al.  Rhinitis, rhinosinusitis and quality of life in children , 2007, Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology.

[5]  P. Kuna,et al.  The effect of 4 weeks treatment with desloratadine (5mg daily) on levels of interleukin (IL)-4, IL-10, IL-18 and TGF beta in patients suffering from seasonal allergic rhinitis. , 2007, Pulmonary pharmacology & therapeutics.

[6]  D. Solé,et al.  Inhaled corticosteroids in the treatment of respiratory allergy: safety vs. efficacy. , 2006, Jornal de pediatria.

[7]  P. Górski,et al.  Montelukast with desloratadine or levocetirizine for the treatment of persistent allergic rhinitis. , 2006, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.

[8]  C. Bachert,et al.  Efficacy and safety of montelukast in adults with asthma and allergic rhinitis. , 2006, Respiratory medicine.

[9]  C. Naspitz,et al.  Prevalence of symptoms of asthma, rhinitis, and atopic eczema among Brazilian children and adolescents identified by the International Study of Asthma and Allergies in Childhood (ISAAC) - Phase 3. , 2006, Jornal de pediatria.

[10]  P. O'Byrne,et al.  Effects of intranasal fluticasone and salmeterol on allergen‐induced nasal responses , 2006, Allergy.

[11]  S. Durham,et al.  Single dose topical corticosteroid inhibits IL‐5 and IL‐13 in nasal lavage following grass pollen challenge , 2005, Allergy.

[12]  G. Marseglia,et al.  Desloratadine and levocetirizine improve nasal symptoms, airflow, and allergic inflammation in patients with perennial allergic rhinitis: a pilot study. , 2005, International immunopharmacology.

[13]  S. Durham,et al.  Topical corticosteroid inhibits interleukin‐4, ‐5 and ‐13 in nasal secretions following allergen challenge , 2005, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.

[14]  W. Henderson,et al.  The role of leukotrienes in allergic rhinitis. , 2005, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.

[15]  C. Pashos,et al.  Economic impact and quality-of-life burden of allergic rhinitis , 2004, Current medical research and opinion.

[16]  G. Ciprandi,et al.  The effect of budesonide on the cytokine pattern in patients with perennial allergic rhinitis. , 2003, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.

[17]  G. Ciprandi,et al.  Nasal cytokine modulation by montelukast in allergic children: a pilot study. , 2003, European annals of allergy and clinical immunology.

[18]  S. Fineman.  The burden of allergic rhinitis: beyond dollars and cents. , 2002, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.

[19]  R. Naclerio,et al.  Effects of Intranasal Azelastine on the Response to Nasal Allergen Challenge , 2002, The Laryngoscope.

[20]  David Skoner,et al.  Allergic rhinitis: definition, epidemiology, pathophysiology, detection, and diagnosis. , 2001, The Journal of allergy and clinical immunology.

[21]  N. Rosário,et al.  [Inflammatory mediators, cell counts in nasal lavage and computed tomography of the paranasal sinuses in atopic children] , 2001, Jornal de pediatria.

[22]  E. Meltzer,et al.  Quality of life in adults and children with allergic rhinitis. , 2001, The Journal of allergy and clinical immunology.

[23]  T. Platts-Mills,et al.  The role of intervention in established allergy: avoidance of indoor allergens in the treatment of chronic allergic disease. , 2000, The Journal of allergy and clinical immunology.

[24]  C. Naspitz,et al.  [Intranasal azelastine in the treatment of perennial allergic rhinitis in children]. , 1996, Jornal de Pediatria.

[25]  P. Howarth,et al.  Cytokine immunoreactivity in seasonal rhinitis: regulation by a topical corticosteroid. , 1995, American journal of respiratory and critical care medicine.

[26]  D. Ownby.  Allergy testing: in vivo versus in vitro. , 1988, Pediatric clinics of North America.

[27]  G. Settipane,et al.  Long-term risk factors for developing asthma and allergic rhinitis: a 23-year follow-up study of college students. , 1994, Allergy proceedings : the official journal of regional and state allergy societies.